1. β-blockers were associated with lower all-cause mortality in patients with heart failure with preserved ejection fraction (HFPEF).
2. There was no association observed between β-blockers use in patients with HFPEF and outcome when the outcome was expanded to include either all-cause mortality or hospitalization for heart failure.
Evidence Rating Level:...
1. Patients of increasing age or comorbid cardiac conditions were found to be at an increased risk of trastuzumab-related congestive heart failure (CHF).
2. Further studies are needed to confirm an association between frequency of administration and CHF.
Evidence rating level: 2 (Good)
Study Rundown: Trastuzumab, a humanized monoclonal antibody, is...